Elapegademase

Summary

Elapegademase (CHEMBL3990026) is an approved enzyme (ATC L03AX21); indicated across 3 conditions including neoplasm and severe combined immunodeficiency.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: L03AX21
• Indications: 3 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990026
Name	Elapegademase
Type	Enzyme
Max phase	4
ATC	L03AX21

Also known as: Elapegademasa, Elapegademase, Elapegademase lvlr, Elapegademase-lvlr, EZN-2279, EZN2279, Revcovi, ELAPEGADEMASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
severe combined immunodeficiency	4	MONDO:0015974	MONDO:0015974

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01420627	PHASE3	COMPLETED	EZN-2279 in Patients With ADA-SCID
NCT03878069	Not specified	COMPLETED	Registry Study of Revcovi Treatment in Patients With ADA-SCID

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).